cln-978
cln-978: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | Phase 1 |
FDA Decisions
FDA_MeetingFDA cleared the IND for CLN-978 in systemic lupus erythematosus, permitting initiation of a global Phase 1 U.S. trial with a 10 microgram starting dose.(CGEM)
Frequently asked questions
Who is developing cln-978?
cln-978 is being developed by Cullinan Therapeutics, Inc..
What is cln-978's latest FDA decision?
The most recent tracked FDA decision for cln-978 is FDA_Meeting for FDA cleared the IND for CLN-978 in systemic lupus erythematosus, permitting initiation of a global Phase 1 U.S. trial with a 10 microgram starting dose., dated October 16, 2024.
Get deeper analysis on cln-978
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis